AuntMinnie

APRIL 11, 2024

This puts shear stress on the tumor endothelium and activates the production of ceramide, a radiosensitizer. Here, transient cavitation is activated via ultrasound-triggered microbubble destruction. The increase in ceramide leads to an increase in tumor cell death. The average tumor diameter recorded was 4.2

Disease 279

Disease Radiosensitivity Ultrasound MRI 279

AuntMinnie

NOVEMBER 9, 2023

Ionizing radiation] exposure in early childhood may be associated with an increased risk of malignancy with neonates at especially higher risk due to their higher radiosensitivity and longer life expectancy than adults,” according to presenter Jeannette Wong-Siegel, MD, of the University of Washington in St. Louis, and colleagues.

Radiation 189

Radiation Disease Radiosensitivity Fluoroscopy 189

JVIR

FEBRUARY 19, 2025

Radiosensitizers, such as capecitabine, may enhance the effects of radioembolization, although data are limited. Liver-directed therapy such as Yttrium-90 (Y90) radioembolization may improve progression-free survival (PFS) and overall survival (OS) for patients who progress on systemic therapy.

Radiosensitivity 40

Radiosensitivity 40

JVIR

JUNE 14, 2024

To provide guidance, via multidisciplinary consensus statements, on the safety interactions between systemic anticancer agents (such as radiosensitizing chemotherapy, immunotherapy, targeted therapy and peptide receptor radionuclide therapy) and transarterial radioembolization (TARE) with yttrium-90 (90Y) labeled microspheres in the treatment of primary (..)

Radiosensitivity 73

Radiosensitivity 73

JVIR

FEBRUARY 21, 2024

It also acts as a radiosensitizer that can be combined with transarterial radioembolization (TARE) to treat primary and secondary liver tumors. Capecitabine has been proven effective as adjuvant chemotherapy for resectable biliary tract cancer (BTC).

Radiosensitivity 40

Radiosensitivity IT 40

Imaging Technology

APRIL 10, 2024

This may be due to inhibition of the MEK-MAPK pathway during DNA damage response, resulting in radiosensitization of cancer cells to 177Lu-rhPSMA-10.1. Results from this preclinical study presented at AACR demonstrated a synergistic therapeutic effect between 177Lu-rhPSMA-10.1 and an MEK inhibitor.

Radiopharmaceuticals 105

Radiopharmaceuticals Radiosensitivity Medical Diagnostic 105

Imaging Technology

NOVEMBER 26, 2023

“I anticipate that the benefit of radiopharmaceuticals will be maximized by combining radiopharmaceutical therapies with a vast array of other agents including immunotherapies, chemotherapeutics, radiosensitizers and radioprotectors.

Clinic 78

Clinic Radiopharmaceuticals Radiosensitivity Pharmaceutical 78